IDEAYA BIOSCIENCES, INC. (IDYA)
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
📈 **POSITIVE** • Medium confidence analysis (72%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business